ReviewEye (London, England)2025
Updates on novel and traditional OCT and OCTA biomarkers in nAMD.
Review in Eye (London, England), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Retinal and choroidal morphometric analysis in fellow eye of unilateral wet age related macular degeneration using optical coherence tomography angiography.BMC ophthalmology · 2026Article
- Improved method for optical coherence tomography angiography: from reconstruction to clinical indicator quantification.Journal of biomedical optics · 2026Article
- Cracking nAMD's code: interface traction, a unified double-layer sign, and photoreceptor revival on OCT/OCTA.Eye (London, England) · 2025Article
- Integrating Artificial Intelligence and Precision Therapeutics for Advancing the Diagnosis and Treatment of Age-Related Macular Degeneration.Bioengineering (Basel, Switzerland) · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Predictivity of optical coherence tomography (OCT) examination for the development of neovascular age-related macular degeneration (nAMD) was demonstrated to be superior compared to other methods, suggesting it as an elective method for screening purposes. Moreover, OCT and OCT angiography (OCTA) have enabled us to provide accurate prognostic information to nAMD patients. Along with well-known prognostic biomarkers, such as the presence of reticular pseudodrusen, the volume of the pigment epithelial detachment (PED), subretinal fluid (SRF), intraretinal fluid (IRF) and hyperreflective foci (HRF), emerging parameters show promising results and may allow a further refinement of prediction and customization of treatment and follow up strategies. This review of the literature discusses the main OCT and OCTA biomarkers reported in literature for nAMD, with a special focus on recent updates on the subject. Future perspectives of clinical applications include the development of artificial intelligence models considering all the described biomarkers to allow automatic and detailed characterization of each lesion based on imaging information.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.